The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an investigator-initiated trial for NS-089/NCNP-02, known as “brogidirsen.” This innovative treatment for Duchenne muscular dystrophy (DMD), jointly developed with Nippon Shinyaku Co., Ltd., represents a significant advancement in exon 44 skipping therapy.
Table of Contents
Brogidirsen Clinical Trial Results
- Brogidirsen shows dose-dependent dystrophin restoration in DMD patients’ trials.
- High-dose brogidirsen reached 24.47% of normal dystrophin level in the DMD cohort.
- The trial demonstrated therapeutic benefits with stable or improved motor function and a favourable safety profile with no severe adverse events.
- Serum biomarkers for DMD were identified, including PADI2, TTN, MYOM2, and MYLPF.
- Brogidirsen showed high efficiency in DMD urine-derived cells, supporting human trials.
What is Brogidirsen?
Brogidirsen (NS-089/NCNP-02) is a nucleic acid drug co-discovered by Nippon Shinyaku and NCNP, and is expected to be a therapeutic drug for DMD patients with dystrophin gene mutations amenable to exon 44 skipping.
Learn More: Upcoming Exon 44 Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy
- Follow Us -
انا مريضة دوشين عمري 34 سنة كيف استطيع الدخول مع مجموعة المرضى في التجارب السريرية البشرية
أنصحك بكتابة بريد إلكتروني إلى عناوين البريد الإلكتروني أدناه، موضحًا حالتك بالتفصيل. (عمرك، الإكسونات الخاصة بك، الأدوية التي تستخدمها، وما إلى ذلك.)
E-mail: tsugu56(a)ncnp.go.jp
E-mail: shigemori(a)ncnp.go.jp
E-mail: kouhou(a)ncnp.go.jp